The Onco’Zine Brief – Broadening the Understanding of Cancer and Cancer...

Cancer Kills. With more than 8.2 million deaths in 2012, it is the second leading cause of death globally. In addition, the economic impact...

An end to Smoking: Tackling the Leading Cause of Preventable Disease...

According to the latest data from the Office of Smoking and Health of the U.S. Centers for Disease Control and Prevention, almost 90% of...

The Power of The Immune System

Earlier this month, in The Onco’Zine Brief, our weekly radio broadcast and podcast, Sonia Portillo and I interviewed Joshua A. Hill, MD, an Associate...

Physicians Sue over Monopolistic “Maintenance of Certification”

Before 1990, American physicians who had completed 3 years or more of rigorous training in a specialty and passed an examination were awarded lifetime...

Can Corporate Heavyweights Really Tackle the Healthcare Issue?

Three of the most respected corporations in America announced plans this week to start a new company to tackle rising healthcare costs. The three...

Closing the Knowledge Gap to Improve Lung Cancer Treatment

Lung cancer is the leading cause of cancer death worldwide. The deadliness of the disease can be partially attributed to the late onset of...

San Antonio Breast Cancer Symposium – Shifting Paradigms in Targeted Therapies

This year’s San Antonio Breast Cancer Symposium (SABCS) is taking place on December 5-9th, 2017, and it is expected to bring in a broad...

ASH 2017: Expect an Invaluable Educational Experience

This year - from December 9 - 12, Oncologists and Hematologists will gather again in Atlanta, GA, the South's largest and most vibrant city,...

Charitable Efforts Know No Boundaries When Helping the Underserved— Stakeholders Strive...

When a steady, relied-upon source of funding was ending, a public-private coalition of concerned stakeholders was created in Arizona to ensure that certain critical...

It’s Just the Beginning, but Much More Work Remains

Yesterday’s U.S. Food and Drug Administration’s (FDA) approval of the immunotherapy drug, CTL019 (tisagenlecleucel-T | Kymriah®; Novartis), for treatment of childhood Acute Lymphoblastic Leukemia...

LATEST